

4-AcO-DMT, 1 as 4-OH-DMT (psilocin) and 1 as an unknown substance. Totally 48 samples were presented as 4-AcO-DMT: apart from the aforementioned 46 samples another 2 samples were presented as 4-AcO-DMT were no substance was found. In 37 samples containing 4-AcO-DMT (77.08%) presence of 4-OH-DMT was also found. From 2009 to 2010 9 samples were delivered as 4-AcO-DMT, 16 from 2011 to 2012 and 23 from 2013 to 2014 4-AcO-DMT was the 24th most handled substance during the whole period and representing 62.33% (48 out of 77) of the psilocin related substances [4-AcO-DMT (n=48), mushrooms (n=12), 4-AcO-DIPT (n=12), 4-AcO-MIPT (n=1) and psilocybin (n=1)].

Conclusion and Discussion: Results show a recent increase in 4-AcO-DMT analysis that could translate a progressive rise in its recreational use gaining ground to other regulated tryptamines. Whether psilocin found on samples is a result of adulteration, degradation or an analytical artefact should be further studied. Clinical relevance comes from its growing use and the absence of scientific evidence on humans, not even a case report, therefore relying on users subjective experience to predict the effects of the substance. Awareness should be raised to clinicians and scientist in order to promote evidence on this substance clinical effects as well as epidemiological data at a larger scale.

References

- [1] Papaseit, E., Farré, M., Schifano, F., Torrens, M., 2014. Emerging drugs in Europe. *Current Opinion in Psychiatry*, 27, 243–50.
- [2] EMCDDA 2015. New psychoactive substances in Europe. An update from the EU Early Warning System. Lisbon.
- [3] Nichols, D., Frescas, S., 1999. Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin. *Synthesis* 6, 935–938.
- [4] Hill S., Thomas S., 2011. Clinical toxicology of newer recreational drugs. *Clinical Toxicology* 49, 705–719.

Disclosure statement: Supported in part by grants of Instituto de Salud Carlos III-FEDER (RTA RD12/0028/0009), and The European Commission (Drug Prevention and Information Programme 2014–16, contract no.: JUST/2013/DPIP/AG/4823, EU-MADNESS project). Lilianna Galindo is a Rio Hortega fellowship (ISC-III CM14/00111).

P6.d.017 Is this really ketamine? The presence of methoxetamine on drug samples delivered as ketamine for substance analysis

P. Quintana^{2*}, A. Palma^{1,5}, M. Grifell^{1,2}, J. Tirado^{3,5}, C. Gil², M. Ventura², I. Fornís³, S. López², V. Perez^{1,5}, M. Torrens^{1,3,5}, M. Farré^{3,4,5}, L. Galindo^{1,3,5} ¹Parc de Salut Mar, Institut de Neuropsiquiatria i Addiccions, Barcelona, Spain; ²Asociación Bienestar y Desarrollo, Energy Control, Barcelona, Spain; ³Institut Municipal d'Investigació Mèdica IMIM, Grup de recerca en addiccions, Barcelona, Spain; ⁴Hospital Germans Trias i Pujol, Servei de Farmacologia Clínica, Barcelona, Spain; ⁵Universitat Autònoma de Barcelona, Departament de Psiquiatria i Medicina Legal, Barcelona, Spain

Introduction: New psychoactive substances (NPS) are substances that mimic the effect of traditional drugs, have recently become available and that are not world-wide regulated. They often intend to mimic the effect of controlled drugs [1] becoming a public health concern. In 2014 101 new substances were reported for the first time in the EU [2]. Methoxetamine, an NPS, is a dissociative hallucinogenic acting as a NMDA receptor antagonist clinically and pharmacologically similar to ketamine [3]. It differs from

ketamine on its higher potency and duration as well as on its serotonergic effects probably leading to more severe side effects. It is a non-regulated substance in Spain sold as a ketamine substitute [2]. It has been one of the 6 substances requiring risk assessment by EMCDDA during 2014 [3] and case reports described fatal outcomes related with its use [4].

Objective: The aims of this study are (1) to explore the presence of methoxetamine from the samples handled to and analyzed by Spanish harm-reduction service Energy Control and (2) to determine whether methoxetamine is being delivered as ketamine for recreational use.

Materials and Methods: All samples analyzed from January 2010 to March 2015 handled as methoxetamine or in which methoxetamine was found were studied. Energy Control is a Spanish harm-reduction non-governmental organization that offers users the possibility of analyzing the substances they intend to consume. Substance analysis is carried out by Thin Layer Chromatography and Gas Chromatography–Mass Spectrometry.

Results: During the period of study, from 16.6605 samples obtained, methoxetamine was found in 138 (0.83%). From these 138 samples containing methoxetamine, only 69 (50%) were delivered as such, 50 (36%) were delivered as ketamine and 19 (14%) as other substances like (cocaine=3, amphetamine=2 and mephedrone=2, among others). In the 138 samples that contained methoxetamine, other compounds were also found in 42 (30%), being synthesis by-products the most frequent ones (n=23), followed by unknown substances (n=23), caffeine (n=17), mephedrone (n=6) and MDMA (n=3), among others.

Conclusion: The results of this study show a significantly growing ratio of samples handled as ketamine actually containing methoxetamine. This fact is clinically relevant since methoxetamine has a longer higher effect and fatal outcomes have been reported as connected to its recreational use. Severe side effects might be even more serious considering that users of the substance probably ignore which substance they are actually using. Despite the increasing number of studies on methoxetamine further evidence is needed to clarify the magnitude of methoxetamine delivered as ketamine and its clinical implications at a higher scale.

References

- [1] Papaseit, E., Farré, M., Schifano, F., Torrens, M., 2014. Emerging drugs in Europe. *Current Opinion in Psychiatry*, 27(4), 243–50.
- [2] EMCDDA, 2015. New psychoactive substances in Europe. An update from the EU Early Warning System. Lisbon.
- [3] Corazza, O., Schifano, F., 2012. Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine. *Human Psychopharmacology*, 27(2), 145–9.
- [4] Adamowicz, P., Zuba, D., 2015. Fatal intoxication with methoxetamine. *Journal of Forensic Sciences*, 60 (1), 264–8.
- [5] Morris, H., Wallach, J., 2014. From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. *Drug Testing and Analysis* 6 (7–8), 614–632.

P6.d.018 Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) alone and in combination affect brain activity during rest

H.H. Van Hell^{1*}, S. Broyd¹, L. Greenwood¹, R. Croft¹, N. Solowij¹ ¹University of Wollongong, School of Psychology, Wollongong, Australia

Purpose of the study: Δ⁹-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most important constituents of cannabis. CBD has gained interest in recent years due to its